Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04558840 · ClinicalTrials.gov registry record · NA

Enhanced Recovery After Bilateral Reduction Mammaplasty

A NA study, sponsored by University of Texas Southwestern Medical Center.

Terminated
Registry status
NA
Development phase
54
Enrollment target

NCT04558840: Clinical Trial NA study, sponsored by University of Texas Southwestern Medical Center.

NCT04558840 is a NA study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 54 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04558840, a NA study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.

TERMINATED
Registry status
NA
Development phase
54 participants
Enrollment target

Study Summary

This single-center, clinical trial is being conducted to determine whether non-narcotic pain regiments are as effective as narcotic-based regiments in reducing post-operative pain in patients undergoing breast reduction in the outpatient setting.

Primary Outcome

Determine the efficacy of non-narcotic pain regiments in patients undergoing breast reduction surgery and compare it to narcotic-based pain regiments in improving post-operative pain in patients undergoing breast reduction surgery. Patients will be asked to rate their pain from a scale of 0 ("No Pain") to 10 ("Pain as bad as you can imagine").

Interventions

  • PROCEDURE Macromastia

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2021-10-15
Est. Completion 2023-11-30
Phase NA

Why NCT04558840 stopped before completion

NCT04558840 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 1 intervention - of which Macromastia is the first listed.

NCT04558840 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04558840 about?

NCT04558840 is a clinical study titled "Enhanced Recovery After Bilateral Reduction Mammaplasty". This single-center, clinical trial is being conducted to determine whether non-narcotic pain regiments are as effective as narcotic-based regiments in reducing post-operative pain in patients undergoing breast reduction in the outpatient setting.

What is the current status of trial NCT04558840?

This trial is currently terminated. It is a NA study. The enrollment target is 54 participants. The study started on 2021-10-15. Estimated completion is 2023-11-30.

What interventions are being tested in trial NCT04558840?

The interventions under investigation include: Macromastia (PROCEDURE).

Who is sponsoring clinical trial NCT04558840?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04558840's enrollment target sits among peer trials

54 1268th of 2000 higher than 730 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01269853 · 54 participants · Phase 1

    Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

  • NCT02390752 · 54 participants · Phase 1

    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  • NCT02991248 · 54 participants · NA

    Improve Dynamic Lateral Balance of Humans With SCI

  • NCT02993900 · 54 participants · NA

    Image-Guided Gynecologic Brachytherapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04558840, the US trial registry maintained by the National Library of Medicine. NCT04558840 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.